Volume 5 Issue 1
2021-03-04 Review Article
Abstract
The RNA interference (RNAi) technique is a new modality for cancer therapy, and several candidates are being tested clinically. Nanotheranostics is a rapidly growing field combining disease diagnosis and therapy, which ultimately may add in the development of ‘personalized medicine’.
Technologies on theranostic nanomedicines has been discussed. We designed and developed bioresponsive and fluorescent hyaluronic acid-iodixanol nanogels (HAI-NGs) for targeted X-ray computed tomography (CT) imaging and chemotherapy of MCF-7 human breast tumors. HAI-NGs were obtained with a small size of ca. 90 nm, bright green fluorescence and high serum stability from hyaluronic acid-cystamine-tetrazole and reductively degradable polyiodixanol-methacrylate via nanoprecipitation and a photo-click crosslinking reaction. This chapter presents an over view of the current status of translating the RNAi cancer therapeutics in the clinic, a brief description of the biological barriers in drug delivery, and the roles of imaging in aspects of administration route, systemic circulation, and cellular barriers for the clinical translation of RNAi cancer therapeutics, and with partial content for discussing the safety concerns. Finally, we focus on imaging-guided delivery of RNAi therapeutics in preclinical development, including the basic principles of different imaging modalities, and their advantages and limitations for biological imaging. With growing number of RNAi therapeutics entering the clinic, various imaging methods will play an important role in facilitating the translation of RNAi cancer therapeutics from bench to bedside.
2021-02-01 Case Report
Summary
We evaluated a total of 115 patients diagnosed with anal cancer, who were treated at our clinic from 1995 to 2012. Their average age was 61 years, most often were diagnosed in stages II and III, in most cases it was a squamous cell carcinoma located in the anal canal. The mean follow-up was 83 months (minimum 1 month and maximum 240 months). We combined external radiotherapy with boost of brachytherapy or boost of external radiotherapy and possibly a combination of both boosts. Half of the patients received concomitant chemotherapy. We specifically evaluated local tumor regression, overall survival and the impact to therapeutic effect of the chosen irradiation technique. Complete regression was achieved in 92 patients, partial regression in 21 patients. Overall survival, regardless of stage, was 80% 3-year, 74% 5-year and 67% 10-year. The age of patients, the size of their own primary tumor and the therapeutic method used had a statistically significant effect on survival - especially the importance of brachytherapy was irreplaceable.
Recent Articles
2021-03-04 Review Article
Loutfy H Madkour*
2021-02-01 Case Report
Kubecová M, Vránová J, Šejdová M and Regináčová K*
2020-12-22 Research Article
Roopa Ganta, Shehnaz R Kantharia, Bhavin Bhupendra Shah, Rajinikant Mohan Vasava, Tushar Vishnuprasad Vaishnav and Rajesh A Kantharia*
Abstract Read Full Article HTMLDOI: 10.29328/journal.jro.1001033 Citation
2020-05-06 Review Article
Bora Uysal*, Hakan Gamsız, Ferrat Dincoglan, Omer Sager, Selcuk Demiral and Murat Beyzadeoglu
Abstract Read Full Article HTMLDOI: 10.29328/journal.jro.1001032 Citation
2020-04-15 Case Report
Harsumeet S Sidhu* and Sonia Sandeep
Abstract Read Full Article HTMLDOI: 10.29328/journal.jro.1001031 Citation
2019-12-05 Case Report
Meng Liu, Kaifu Wu and Yongming Tan*
Abstract Read Full Article HTMLDOI: 10.29328/journal.jro.1001030 Citation
2019-07-21 Case Report
2019-02-14 Research Article
Ryosuke Kohno*, Wenhua Cao, Pablo Yepes, Xuemin Bai, Falk Poenisch, David R Grosshans, Tetsuo Akimoto and Radhe Mohan
Abstract Read Full Article HTMLDOI: 10.29328/journal.jro.1001027 Citation
2018-11-07 Research Article
Sadia Ali, Adeena Khan*, Kiran Sarfaraz, Saba Akram, Mariam Javaid and Asma Bano
Abstract Read Full Article HTMLDOI: 10.29328/journal.jro.1001026 Citation
































